A Safety and Efficacy of Intrathecally Administered ION283 in Patients With Lafora Disease

NCT06609889 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

RECRUITING

Status

10

Enrollment

OTHER

Sponsor class

Conditions

Lafora Disease

Interventions

GENETIC: ION283

Sponsor

Berge Minassian

Collaborators

[object Object]